Pharma & Biotech Global Week in Review 4 August 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Gemzar (Gemcitabine) – US: CAFC affirms invalidity of Lilly’s Gemzar patent for obviousness-type double patenting: Sun Pharmaceuticals v. Eli Lilly (Orange Book Blog) (Patently-O) (Gray on Claims) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

 

General

Civil Society Groups warn on ACTA and access to medicines (Michael Geist)

The A to Z Generics iPad app (SPC blog)

Global AIDS conference sees pledge of access, call for funding; IP rights discussed (IP Watch)

Brazil: Bayer ‘Liberty Link’ maize banned in Brazil (IP Watch)

Brazil: More on patentability of medicines from Brazil (IP tango)

India: Revised list of pharmaceutical product patents and Controller decisions (Generic Pharmaceuticals and IP)

India: ‘Prioritising’ pharmaceutical patents in India? (Spicy IP)

Mexico to issue regulations for approval of ‘biocomparable’ drugs (Patent Docs)

US: Access to medicine groups call for a halt on USTR’s 301 process (Spicy IP)

US: BioOhio annual conference goes on the road for 2010 (Patent Baristas)

US: Drug patent expirations in August 2010 (Biotech Blog)

US: Synthetic biology: what’s the agenda? August 13, 2010 (Biotech Blog)

US: Preserve Access to Affordable Generics Act included in FY 2011 Financial Services and General Government Appropriations Bill (FDA Law Blog)

US: Senate removes Pay-For-Delay provision from Appropriations Bill (Patent Docs)

Products

Actos (Pioglitazone) – US: Patent infringement complaint filed following Paragraph IV certification:  Takeda Pharmaceutical Co. et al. v. Wockhardt Ltd. et al. (Patent Docs)

Angiomax (Bivalirudin) – US: MDCO prevails in Angiomax PTE case – District Court grants summary judgment; Will the PTO appeal? (FDA Law Blog)

Aricept (Donepezil) – US: Teva agrees to dismiss suit with Eisai over Aricept patent (Patent Docs)

Carbatrol (Carbamazepine) – US: Patent infringement complaint following a Paragraph IV certification: Shire LLC v. Taro Pharmaceutical Industries Ltd. et al. (Patent Docs)

Dovonex (Calcipotriol) – UK: Interest on damages for infringement not a correctable error: Leo Pharma A/S and another v Sandoz Ltd (PatLit)

Eloxatin (Oxaliplatin) – US: DC District Court denies Sanofi summary judgment motion in generic Eloxatin case; Refuses to reinstate 30-month stay on ANDA approvals (FDA Law Blog) (Orange Book Blog)

FazaClo (Clozapine) – US: Patent infringement complaint filed following a Paragraph IV certification: Cima Labs, Inc. et al. v. Mylan Pharmaceuticals Inc. (Patent Docs)

Gemzar (Gemcitabine) – US: CAFC affirms invalidity of Lilly’s Gemzar patent for obviousness-type double patenting: Sun Pharmaceuticals v. Eli Lilly (Orange Book Blog) (Patently-O) (Gray on Claims) (Patent Docs)

Gynazole-1 (Butoconazole) – US: Perrigo confirms filing for generic version of Gynazole-1 cream and announcement of patent infringement lawsuit by KV Pharma (SmartBrief)

Hectorol (Doxercalciferol) – US: Patent infringement complaint following a Paragraph IV certification: Genzyme Corp. v. Roxane Laboratories Inc. (Patent Docs)

Namenda (Memantine) – US: Forest and Merz Pharma settle Namenda infringement dispute (Patent Docs)

Naropin (Ropivacaine) – US: Patent infringement complaint filed following ANDA filing: APP Pharmaceuticals, LLC v. Navinta LLC et al. (Patent Docs)

Prandin (Repaglinide) – US: Federal Circuit denies rehearing petition in PRANDIN patent use code case; Dissents argue that ‘Section viii’ carve-outs eviscerated (FDA Law Blog)

Solodyn (Minocycline) – US: Medicis Pharmaceuticals settles Solodyn litigation with Mylan (Patent Docs)

Ziana (Clindamycin, Treinoin) – US: Patent infringement complaint filed based on NDA to manufacture Veltin: Medicis Pharmaceutical Corp. v. Stiefel Laboratories, Inc. (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: